Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.83 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.83 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.44 |
| ▸ | SSTR2 | P30874 | 4/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.44 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.42 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.42 |
| ▸ | TERF2 | Q15554 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | LDHB | P07195 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29692248 | 1.00 | KDM1A (0.83) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL17655767 | 0.95 | KDM1A (0.81) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL17655763 | 0.95 | KDM1A (0.81) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL16426329 | 0.95 | KDM1A (0.81) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| Desfa-[Dab1]Polymyxin B SCHEMBL29354296 | 0.94 | KDM1A (0.86) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL21258440 | 0.94 | KDM1A (0.82) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL21504107 | 0.93 | KDM1A (0.77) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL21335169 | 0.93 | KDM1A (0.79) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL17992329 | 0.93 | KDM1A (0.79) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL24564765 | 0.93 | KDM1A (0.80) | KDM1ARCOR1SSTR5SSTR2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014966-B2 | Compounds and therapeutics uses thereof | CENTUARI THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-20190248838-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2019-08-15 | — | — | US | disclosed |
| WO-2018051085-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248838-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, MYD88, CD47 | KDM1A 4216/4885RCOR1 3890/4885SSTR5 4825/4885 |
| US-11014966-B2 | Compounds and therapeutics uses thereof | MYD88, MAVS, CD47 | KDM1A 4104/4885RCOR1 4159/4885SSTR5 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.